LLLing Liu

Ling Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling Liu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Joseph Rosenbluh

    Cancer Research Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia

    3 shared publications
  • Laura Perlaza-Jimenez

    Department of Biochemistry and Molecular Biology and Cancer program, Biomedicine Discovery Institute, Monash University, Melbourne, Australia

    2 shared publications
  • Xinqi Xi

    Department of Biochemistry and Molecular Biology and Cancer program, Biomedicine Discovery Institute, Monash University, Melbourne, Australia

    2 shared publications
  • Azelle Hawdon

    Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Camden, NSW, 2570, Australia

    1 shared publication
  • Catherine Elizabeth Caldon

    Garvan Institute of Medical Research, Sydney, Australia

    1 shared publication
  • Dmitri Mouradov

    Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research

    1 shared publication

Latest Publications

  • Open Access

    SRP19 and the protein secretion machinery is a targetable vulnerability in cancers with APC loss

    by Xinqi Xi, Ling Liu, Natasha Tuano, Julien Tailhades, Dmitri Mouradov, Jason Steen, Oliver Sieber, Max Cryle, Tu Nguyen-Dumont, Eva Segelov, et al.

    Loss of the tumor suppressor gene (TSG) Adenomatous Polyposis Coli ( APC ) is a hallmark event in colorectal cancers. Since it is not possible to directly target a TSG, no treatment options are available for these patients. Here, we identify SRP19 and the protein secretion machinery as a unique vulnerability in cancers with heterozygous APC loss. SRP19 is located 15 kb from APC and is almost always codeleted in these tumors. Heterozygous APC/SRP19 loss leads to lower levels of SRP19 mRNA and protein. Consequently, cells with APC/SRP19 loss are vulnerable to partial suppression of SRP19 . Moreover, we show that SRP19 is rate limiting for the formation of the Signal Recognition Particle, a complex that mediates ER-protein translocation, and thus, heterozygous SRP19 loss leads to less protein secretion and higher levels of ER-stress. As a result, low-dose arsenic trioxide induces ER-stress and inhibits proliferation in cultured cell lines and animal models. Our work identifies a strategy to treat cancers with APC deletion and provides a framework for identifying and translating vulnerabilities associated with loss of a TSG.


  • Open Access

    SAM-DNMT3A, a strategy for induction of genome-wide DNA methylation, identifies DNA methylation as a vulnerability in ER-positive breast cancers

    by Mahnaz Hosseinpour, Xinqi Xi, Ling Liu, Luis Malaver-Ortega, Laura Perlaza-Jimenez, Jihoon E. Joo, Harrison M. York, Jonathan Beesley, C. Elizabeth Caldon, Pierre-Antoine Dugué, et al.

    DNA methylation is an epigenetic mark that plays a critical role in regulating gene expression. DNA methyltransferase (DNMT) inhibitors, inhibit global DNA methylation and have been a key tool in studies of DNA methylation. A major bottleneck is the lack of tools to induce global DNA methylation. Here, we engineered a CRISPR based approach, that we initially designed, to enable site-specific DNA methylation. Using the synergistic activation mediator (SAM) system, we unexpectedly find that regardless of the targeted sequence any sgRNA induces global genome-wide DNA methylation. We term this method SAM-DNMT3A and show that induction of global DNA methylation is a unique vulnerability in ER-positive breast cancer suggesting a therapeutic approach. Our findings highlight the need of caution when using CRISPR based approaches for inducing DNA methylation and demonstrate a method for global induction of DNA methylation.


  • Systematic loss-of-function screens identify pathway-specific functional circular RNAs

    by Ling Liu, Matthew Neve, Laura Perlaza-Jimenez, Xinqi Xi, Jacob Purcell, Azelle Hawdon, Simon J. Conn, Jennifer Zenker, Pablo Tamayo, Gregory J. Goodall, et al.

    Circular RNA (circRNA) is covalently closed, single-stranded RNA produced by back-splicing. A few circRNAs have been implicated as functional; however, we lack understanding of pathways that are regulated by circRNAs. Here we generated a pooled short-hairpin RNA library targeting the back-splice junction of 3,354 human circRNAs that are expressed at different levels (ranging from low to high) in humans. We used this library for loss-of-function proliferation screens in a panel of 18 cancer cell lines from four tissue types harbouring mutations leading to constitutive activity of defined pathways. Both context-specific and non-specific circRNAs were identified. Some circRNAs were found to directly regulate their precursor, whereas some have a function unrelated to their precursor. We validated these observations with a secondary screen and uncovered a role for circRERE(4–10) and circHUWE1(22,23), two cell-essential circRNAs, circSMAD2(2–6), a WNT pathway regulator, and circMTO1(2,RI,3), a regulator of MAPK signalling. Our work sheds light on pathways regulated by circRNAs and provides a catalogue of circRNAs with a measurable function.